Literature DB >> 28440193

Neurocognitive Correlates in Driving Under the Influence of Cannabis.

Francesco P Busardò1, Manuela Pellegrini2, Julia Klein3, Natale M di Luca4.   

Abstract

BACKGROUND &
OBJECTIVE: Delta (9)-tetrahydrocannabinol (THC) is the main psychoactive compound in cannabis and is frequently identified in blood samples from apprehended drivers suspected for driving under the influence of drugs. Changing social norms towards cannabis and higher acceptability towards the drug emphasize the need for in-depth understanding of the acute neurocognitive and psychomotor effects caused by cannabis and how these effects are correlated to driving skills and performance.
METHOD: In this review, PubMed, Cochrane Central, Scopus, Web of Science, Science Direct, EMBASE and Google Scholar databases were used to identify and select publications up to January 2017 dealing with acute and chronic neurocognitive effects induced by cannabis and ability to drive. Thirty-six publications were selected for this review. The studies conducted were experimental, using simulators or on-road studies and brain imaging (structural and functional) to better understand the acute and chronic effects on cognitive functions comprised in the short and long-term fitness to drive after cannabis consumption.
CONCLUSION: In a case-crossover self-report study a significant odds ratio increase was found for driving- related injury after combined exposure to cannabis and alcohol compared to cannabis alone (OR of 10.9 and 5.8 respectively). Both, experimental and epidemiological studies have revealed that THC affects negatively both, psychomotor skills and cognitive functions. Studies of the acute effects of cannabis on driving have shown that drivers under the influence of this substance are impaired. Indeed, driving under the influence of cannabis doubles or triples the risk of a crash. Specifically, cannabis use impairs critical-tracking tasks, increases lane weaving, decreases reaction time, and divided attention. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Acute effects; Cannabis; chronic effects; delta (9)-tetrahydrocannabinol; neurocognitive; psychoactive

Mesh:

Substances:

Year:  2017        PMID: 28440193     DOI: 10.2174/1871527316666170424115455

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

Review 1.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

Review 2.  A Clinical Framework for Assessing Cannabis-Related Impairment Risk.

Authors:  Caroline A MacCallum; Lindsay A Lo; Carly A Pistawka; April Christiansen; Michael Boivin; Melissa Snider-Adler
Journal:  Front Psychiatry       Date:  2022-06-24       Impact factor: 5.435

Review 3.  Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs.

Authors:  Francesco Paolo Busardo; Simona Pichini; Manuela Pellegrini; Angelo Montana; Alfredo Fabrizio Lo Faro; Simona Zaami; Silvia Graziano
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review.

Authors:  Lauren Eadie; Lindsay A Lo; April Christiansen; Jeffrey R Brubacher; Alasdair M Barr; William J Panenka; Caroline A MacCallum
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

Review 5.  Recent Medico-Legal Developments on the Issue of Epilepsy and Driver's License Requirements in the Italian and European Legislation.

Authors:  Brenno Mazzariol; Antonella Pastorini; Alessandro di Luca; Natale Mario di Luca
Journal:  Behav Neurol       Date:  2019-09-30       Impact factor: 3.342

6. 

Authors:  Sarah B Windle; Crystal Sequeira; Kristian B Filion; Brett D Thombs; Pauline Reynier; Roland Grad; Carolyn Ells; Mark J Eisenberg
Journal:  CMAJ       Date:  2021-07-12       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.